Attached files

file filename
10-Q - FORM 10-Q - GALECTIN THERAPEUTICS INCd402747d10q.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR33.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A) - GALECTIN THERAPEUTICS INCd402747dex312.htm
EX-32.1 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 - GALECTIN THERAPEUTICS INCd402747dex321.htm
EX-10.3 - EMPLOYMENT AGREEMENT - GALECTIN THERAPEUTICS INCd402747dex103.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A) - GALECTIN THERAPEUTICS INCd402747dex311.htm
EXCEL - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR6.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR9.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR2.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR3.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR1.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR7.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR8.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR4.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR21.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR14.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR17.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR23.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR29.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR32.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR26.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR18.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR30.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR10.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR24.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR20.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR15.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR28.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR13.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR16.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR19.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR27.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR12.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR11.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR25.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR31.htm
XML - IDEA: XBRL DOCUMENT - GALECTIN THERAPEUTICS INCR22.htm
EX-32.2 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 - GALECTIN THERAPEUTICS INCd402747dex322.htm
v2.4.0.6
Consolidated Statement Of Changes In Redeemable Convertible Preferred Stock And Stockholders' Equity (Deficit) (USD $)
In Thousands, except Share data
Total
USD ($)
Series A Preferred Stock
USD ($)
Series C Preferred Stock
USD ($)
Series B-1 12% redeemable convertible preferred stock
USD ($)
Series B-2 12% redeemable convertible preferred stock
USD ($)
Series C super dividend convertible preferred stock
USD ($)
Series A 12% convertible preferred stock
USD ($)
Common Stock
USD ($)
Common Stock
Series A Preferred Stock
Common Stock
Series B One Preferred Stock
Common Stock
Series B Two Preferred Stock
Common Stock
Series C Preferred Stock
Additional Paid-In Capital
USD ($)
Additional Paid-In Capital
Series A Preferred Stock
USD ($)
Additional Paid-In Capital
Series B One Preferred Stock
USD ($)
Additional Paid-In Capital
Series B Two Preferred Stock
USD ($)
Additional Paid-In Capital
Series C Preferred Stock
USD ($)
Deficit Accumulated During the Development Stage
USD ($)
Deficit Accumulated During the Development Stage
Series A Preferred Stock
USD ($)
Deficit Accumulated During the Development Stage
Series B One Preferred Stock
USD ($)
Deficit Accumulated During the Development Stage
Series B Two Preferred Stock
USD ($)
Deficit Accumulated During the Development Stage
Series C Preferred Stock
USD ($)
Beginning Balance at Dec. 31, 2011 $ (2,125)     $ 1,681 $ 2,687 $ 2,154 $ 632 $ 13         $ 66,367         $ (69,137)        
Beginning Balance (in shares) at Dec. 31, 2011       900,000 2,100,000 220 1,562,500 12,919,538                            
Accretion of Series B redeemable convertible preferred stock (130)     13 117                         (130)        
Accretion of beneficial conversion feature for Series B-2 (42)       42                         (42)        
Issuance of common stock and warrants, net of issuance costs of $1,597,000 (in shares)               2,666,722                            
Issuance of common stock and warrants, net of issuance costs of $1,597,000 10,403             3         10,400                  
Issuance of shares related to reverse split of common stock               3,324                            
Convertible preferred stock dividend (in shares)                 31,250 67,259 156,936 46,053                    
Convertible preferred stock dividend   47 33                     103 166 386 127   (56) (166) (386) (94)
Issuance of common stock to a consultant (in shares)               11,348                            
Issuance of common stock to a consultant 26                       26                  
Issuance of common stock upon exercise of warrants               12,177                            
Issuance of common stock upon exercise of options 51,830             51,830                            
Stock-based compensation expense 2,144                       2,144                  
Net loss (7,299)                                 (7,299)        
Ending Balance at Sep. 30, 2012 $ 3,057     $ 1,694 $ 2,846 $ 2,154 $ 632 $ 16         $ 79,719         $ (77,310)        
Ending Balance (in shares) at Sep. 30, 2012       900,000 2,100,000 220 1,562,500 15,966,437